A Double-Blind, Multicentre, Randomized, Three-Period, Three-Treatment, Cross-Over Study to Evaluate the Effect of BGF MDI, BFF MDI, and Placebo MDI on Exercise Parameters in Participants With COPD (ATHLOS)
Latest Information Update: 10 Mar 2026
At a glance
- Drugs Budesonide/formoterol/glycopyrrolate (Primary) ; Budesonide/formoterol
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms ATHLOS
- Sponsors AstraZeneca
Most Recent Events
- 05 Mar 2026 Status changed from active, no longer recruiting to completed.
- 19 Dec 2025 Status changed from recruiting to active, no longer recruiting.
- 03 Sep 2025 Planned End Date changed from 10 Sep 2025 to 30 Jan 2026.